



Medicaid and Health Wave
900 SW Jackson Street
Rm. 900-N
Topeka, KS 66612
Phone: 785-296-3981
Fax: 785-296-4813
www.khpa.ks.gov

Drug Utilization Review Board Meeting
Meeting Agenda, Open Session
April 13, 2011, 10:00 a.m.

Meeting Location

HP Enterprise Services ~ Capital and Cedar Crest Rooms
6700 SW Topeka Blvd, Bldg. 283 J, Topeka, Kansas 66619

Board Members

Michael Burke, M.D, Ph.D.	Dennis Grauer, Ph.D.
John Kollhoff, Pharm.D.	Judy McDaniel Dowd, PA-C
Daniel Sutherland, R.Ph.	Roger Unruh, D.O
Kevin Waite, Pharm.D.	

KHPA Staff

Brenda Kuder, R.N.	Marlene Shellenberger
Shelly Liby	

HP Enterprise Services / HID Staff

Karen Kluczykowski, R.Ph.	Debra Quintanilla, R.N.
Lisa Todd, R.Ph.	Nicole Churchwell, Pharm.D.

- I. Call to Order
- II. Announcements
- III. Old Business

A. Review and Approval of January 12, 2011 Meeting Minutes

IV. New Business

- A. Butrans[®] (buprenorphine)
 - i. Quantity Limit
 - ii. *Public Comment
 - iii. Board Discussion/Action
- B. Sprix[®] (ketorolac)
 - i. Day Supply Limit
 - ii. *Public Comment
 - iii. Board Discussion/Action
- C. Femara[®] (letrozole)
 - i. Age Restrictions
 - ii. *Public Comment
 - iii. Executive Session
 - iv. Board Discussion/Action

- D. Lupron[®] (leuprolide)
 - i. New Clinical PA Criteria
 - ii. *Public Comment
 - iii. Executive Session
 - iv. Board Discussion/Action

- E. Abstral[®] (fentanyl)
 - i. New Clinical PA Criteria & Addition to Short-Acting Opioids High Dose Limit
 - ii. *Public Comment
 - iii. Board Discussion/Action

- F. Nuedexta[®] (dextromethorphan/quinidine)
 - i. New Clinical PA Criteria
 - ii. *Public Comment
 - iii. Board Discussion/Action

- G. Egrifta[®] (tesamorelin)
 - i. New Clinical PA Criteria
 - ii. *Public Comment
 - iii. Board Discussion/Action

- H. Acne Medications (Differin[®] (adapalene), Epiduo[®] (adapalene/benzyl peroxide), Azelex[®] & Finacea[®] (azelaic acid), Aczone[®], (dapson), Tazorac[®] (tazarotene), Veltin[®] & Ziana[®] (tretinoin/clindamycin))
 - i. New Clinical PA Criteria
 - ii. *Public Comment
 - iii. Board Discussion/Action

- I. Increlex[®] (mecasermin)
 - i. Revised Clinical PA Criteria
 - ii. *Public Comment
 - iii. Board Discussion/Action

- J. Long-Acting Opioids
 - i. PDL PA Criteria
 - ii. *Public Comment
 - iii. Board Discussion/Action

- K. Short-Acting Opioids
 - i. PDL PA Criteria
 - ii. *Public Comment
 - iii. Board Discussion/Action

- L. Ophthalmic Non-Steroidal Anti-Inflammatory Agents
 - i. PDL PA Criteria
 - ii. *Public Comment
 - iii. Board Discussion/Action

- M. Combination Corticosteroid/Long-Acting Beta-Agonist Inhalers

*Public Comment is limited to five minutes per product; additional time will be allowed at the Board's discretion. Informal comments will be accepted from members of the audience at various points in the agenda.

**** This agenda is subject to change.**

- i. PDL PA Criteria
- ii. *Public Comment
- iii. Board Discussion/Action

N. Fixed Dose Combination Drugs for Hypertension

- i. PDL PA Criteria
- ii. *Public Comment
- iii. Board Discussion/Action

O. Fixed Dose Combination Drugs for Diabetes

- i. PDL PA Criteria
- ii. *Public Comment
- iii. Board Discussion/Action

P. Fixed Dose Combination Drugs for Benign Prostatic Hyperplasia

- i. PDL PA Criteria
- ii. *Public Comment
- iii. Board Discussion/Action

Q. Fixed Dose Combination Drugs for Arthritis

- i. PDL PA Criteria
- ii. *Public Comment
- iii. Board Discussion/Action

R. Fixed Dose Combination Drugs for Hypercholesterolemia

- i. PDL PA Criteria
- ii. *Public Comment
- iii. Board Discussion/Action

S. Fixed Dose Combination Drugs for Migraines

- i. PDL PA Criteria
- ii. *Public Comment
- iii. Board Discussion/Action

V. Public Comment

VI. Adjourn

**Lunch will be provided for DUR Board Members
NEXT MEETING: July 13, 2011**

*Public Comment is limited to five minutes per product; additional time will be allowed at the Board's discretion. Informal comments will be accepted from members of the audience at various points in the agenda.

**** This agenda is subject to change.**